See more : Tarsier Ltd. (TAER) Income Statement Analysis – Financial Results
Complete financial analysis of Elanco Animal Health Inc (5EA.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elanco Animal Health Inc, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- ASM Group S.A. (ASM.WA) Income Statement Analysis – Financial Results
- Sermsang Power Corporation Public Company Limited (SSP.BK) Income Statement Analysis – Financial Results
- Fusion Acquisition Corp. II (FSNB-UN) Income Statement Analysis – Financial Results
- Abbott Laboratories (ABL.DE) Income Statement Analysis – Financial Results
- Nippon Avionics Co., Ltd. (6946.T) Income Statement Analysis – Financial Results
Elanco Animal Health Inc (5EA.DE)
About Elanco Animal Health Inc
Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. The company is headquartered in Greenfield, Indiana and currently employs 5,590 full-time employees. The firm offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The company provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The company also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The company also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. The company also provides products in poultry and aquaculture production.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.41B | 4.76B | 3.27B | 3.07B | 3.07B | 2.89B | 2.91B | 2.91B |
| Cost of Revenue | 1.91B | 2.07B | 1.58B | 1.47B | 1.57B | 1.49B | 1.41B | 1.53B |
| Gross Profit | 2.50B | 2.70B | 1.69B | 1.60B | 1.49B | 1.40B | 1.50B | 1.38B |
| Gross Profit Ratio | 56.63% | 56.59% | 51.79% | 52.17% | 48.68% | 48.29% | 51.64% | 47.28% |
| Research & Development | 380.00M | 424.00M | 338.00M | 270.00M | 246.60M | 251.70M | 265.80M | 291.00M |
| General & Administrative | 1.06B | 1.15B | 996.60M | 760.20M | 735.20M | 779.80M | 784.80M | 916.00M |
| Selling & Marketing | 201.00M | 248.00M | -8.60M | -3.20M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.26B | 1.40B | 988.00M | 757.00M | 735.20M | 779.80M | 784.80M | 916.00M |
| Other Expenses | 0.00 | 556.00M | 359.90M | 200.40M | 197.40M | 221.20M | 170.70M | 163.00M |
| Operating Expenses | 2.33B | 3.03B | 2.22B | 1.45B | 1.18B | 1.25B | 1.22B | 1.37B |
| Cost & Expenses | -416.00M | -963.00M | -644.00M | 24.00M | 2.75B | 2.75B | 2.63B | 2.90B |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 241.00M | 236.00M | 150.00M | 79.00M | 29.60M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 617.00M | 716.00M | 516.90M | 314.50M | 296.00M | 318.40M | 254.40M | 236.90M |
| EBITDA | 1.01B | 1.04B | 499.00M | 669.00M | 630.00M | 486.10M | 537.60M | 395.30M |
| EBITDA Ratio | 22.83% | 21.83% | 15.26% | 21.78% | 14.34% | 2.97% | 7.96% | -0.78% |
| Operating Income | 390.00M | 376.00M | 17.00M | 375.00M | 313.80M | 142.40M | 283.20M | 5.40M |
| Operating Income Ratio | 8.84% | 7.89% | 0.52% | 12.21% | 10.23% | 4.93% | 9.72% | 0.19% |
| Total Other Income/Expenses | -931.00M | -947.00M | -694.00M | -297.00M | -199.70M | -375.00M | -305.60M | -264.90M |
| Income Before Tax | -72.00M | -571.00M | -677.00M | 78.00M | 114.10M | -232.60M | -22.40M | -259.50M |
| Income Before Tax Ratio | -1.63% | -11.99% | -20.70% | 2.54% | 3.72% | -8.05% | -0.77% | -8.92% |
| Income Tax Expense | 6.00M | 88.00M | 103.00M | 10.00M | 27.60M | 78.10M | 25.50M | -48.70M |
| Net Income | -78.00M | -483.00M | -574.00M | 68.00M | 86.50M | -310.70M | -47.90M | -210.80M |
| Net Income Ratio | -1.77% | -10.14% | -17.55% | 2.21% | 2.82% | -10.75% | -1.64% | -7.25% |
| EPS | -0.16 | -0.99 | -1.30 | 0.18 | 0.28 | -0.87 | -0.13 | -0.59 |
| EPS Diluted | -0.16 | -0.99 | -1.30 | 0.18 | 0.28 | -0.87 | -0.13 | -0.59 |
| Weighted Avg Shares Out | 487.50M | 487.20M | 441.40M | 370.30M | 313.70M | 356.20M | 356.20M | 356.20M |
| Weighted Avg Shares Out (Dil) | 488.30M | 487.20M | 441.40M | 370.30M | 313.70M | 356.20M | 356.20M | 356.20M |
Source: https://incomestatements.info
Category: Stock Reports